Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 9/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18001812 | 0.85 | CYP2A6 (0.58) | CYP2A6PTGS1 | |
| SCHEMBL632443 | 0.83 | CYP2A6 (1.00) | CYP2A6ALDH1A1KDM4EPTGS2RAB9A | |
| SCHEMBL29952287 | 0.83 | CYP2A6 (1.00) | CYP2A6ALDH1A1KDM4EPTGS2RAB9A | |
| SCHEMBL6599322 | 0.79 | CYP2A6 (0.46) | CYP2A6MRGPRX4 | |
| SCHEMBL17256151 | 0.79 | CYP2A6 (0.46) | CYP2A6ALDH1A1TSHRTDP1MRGPRX4 | |
| SCHEMBL11766607 | 0.75 | RELA (0.55) | CYP2A6ALDH1A1KDM4E | |
| SCHEMBL16693064 | 0.75 | ALDH1A1 (0.52) | CYP2A6ALDH1A1KDM4ERAB9A | |
| SCHEMBL14178256 | 0.72 | CYP2A6 (0.57) | CYP2A6RAB9ATDP1 | |
| Benzothiophene SCHEMBL27872206 | 0.72 | CYP2A6 (0.56) | CYP2A6ALDH1A1RAB9APTGS1 | |
| SCHEMBL29833385 | 0.72 | CYP2A6 (0.43) | CYP2A6MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104774319-A | Bis(benzothiophene) ethylene polymers and preparation method and application thereof | CHINESE ACAD INST CHEMISTRY | 2015-07-15 | — | — | CN | claimed |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-12-12 | — | — | US | disclosed |
| WO-2023109461-A1 | BENZOTHIOPHENE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 中国科学院上海药物研究所 | 2023-06-22 | — | — | WO | disclosed |
| CN-116265458-A | Benzothiophene derivative, preparation method and application thereof | 中国科学院上海药物研究所 | 2023-06-20 | — | — | CN | disclosed |
| CN-110357789-B | N-substituted acrylamide derivative as DHODH inhibitor and preparation and application thereof | 华东理工大学 | 2022-09-30 | — | — | CN | disclosed |
| EP-3625228-B1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-07-07 | — | — | EP | disclosed |
| US-20210113559-A1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-04-22 | — | — | US | disclosed |
| EP-3625228-A1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2020-03-25 | — | — | EP | disclosed |
| CN-110612299-A | Pyrimidine derivatives as PGE2 receptor modulators | 爱杜西亚药品有限公司 | 2019-12-24 | — | — | CN | disclosed |
| WO-2018210988-A1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-11-22 | — | — | WO | disclosed |
| US-20060052509-A1 | Composition containing carbon nanotubes having coating thereof and process for producing them | MITSUBISHI RAYON CO., LTD. (JP) | 2006-03-09 | — | — | US | disclosed |
| EP-1555257-A1 | PROCESS FOR PRODUCING AROMATIC NITRILE COMPOUND | IHARA CHEMICAL INDUSTRY Co., Ltd. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-6797726-B1 | N-alkoxyalkyl-N,N-dialkylamine derivatives or salts thereof, and remedies for nerve degeneration diseases containing the same | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-09-28 | — | — | US | disclosed |
| US-6593335-B1 | Disease than can be ameliorated with a potassium channel opener in a host mammal, comprising administering to the mammal in need thereof a therapeutically effective amount of the compound of claim 1; said disease is epilepsy, Raynaud's | ABBOTT LABORATORIES | 2003-07-15 | — | — | US | disclosed |
| EP-1194429-A1 | POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2002-04-10 | — | — | EP | disclosed |
| EP-1186594-A1 | N-ALKOXYALKYL-N,N-DIALKYLAMINE DERIVATIVES OR SALTS THEREOF, AND REMEDIES FOR NERVE DEGENERATION DISEASES CONTAINING THE SAME | TOYAMA CHEMICAL CO., LTD. (JP) | 2002-03-13 | — | — | EP | disclosed |
| WO-2000078768-A1 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2000-12-28 | — | — | WO | disclosed |
| EP-0125059-B1 | HERBICIDAL CYCLOHEXANE-1,3-DIONE DERIVATIVES | ICI AUSTRALIA LIMITED (AU) | 1991-02-27 | — | — | EP | disclosed |
| US-4664693-A | POSTEMERGENCE | ICI AUSTRALIA LIMITED (AU) | 1987-05-12 | — | — | US | disclosed |
| EP-0125059-A2 | Herbicidal cyclohexane-1,3-dione derivatives | ICI AUSTRALIA LIMITED (AU) | 1984-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | CYP2A6 131/4885ALDH1A1 468/4885KDM4E 1571/4885 |
| US-20210113559-A1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | PTGER1, PTGER4, PTGER2 | CYP2A6 131/4885ALDH1A1 468/4885KDM4E 1571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.